Small Studies Show High Upadacitinib Response in Alopecia Areata

Across 33 small studies and case series, patients with alopecia areata who received upadacitinib saw their average Severity of Alopecia Tool (SALT) score fall by more than two-thirds, with 89% reaching near-complete scalp regrowth, according to a systematic review and meta-analysis published in the Journal of the American Academy of Dermatology.¹

Off-Label Use Had Outpaced Controlled Trial Data

Upadacitinib, an oral Janus kinase (JAK) inhibitor, is approved for several immune-mediated conditions, including atopic dermatitis, rheumatoid arthritis, and ulcerative colitis, but not for alopecia areata, unlike baricitinib and ritlecitinib. Dermatologists have nonetheless prescribed it off-label for alopecia areata, generating a scattered body of small case series and open-label studies well before large, placebo-controlled trials of the drug for this indication were completed.

The researchers set out to systematically pool that existing, fragmented evidence to estimate upadacitinib's real-world effect on hair regrowth ahead of those larger trials' results.

Following PRISMA guidelines, the researchers combined results from 33 studies, totaling 136 patients, using a random-effects model to account for differences across studies. The pooled population had a mean age of 27.8 years, was 55% female, and had a mean baseline SALT score of 77.1, reflecting fairly extensive hair loss at the start of treatment.

The primary end point was the change in SALT score, assessed over a mean treatment duration of 24 weeks.

The mean SALT score fell by 68.5 points overall (95% CI, 57.8-79.2; P < .0001) and by 79.9 points among patients with severe disease at baseline (SALT greater than 50; P < .001). Across the pooled studies, 94% of patients achieved at least a 50% improvement in SALT score, and 89% reached a SALT score of 20 or less, indicating 80% or more scalp coverage.

Response did not differ significantly between adults and pediatric patients (mean SALT change, –68.9 vs –71.4; P = .852), between higher and lower dosing regimens (–71.1 vs –68.0; P = .82), or between patients who were JAK inhibitor-naive and those who had previously failed a different JAK inhibitor (–68.4 vs –64.6; P = .79).

“Upadacitinib demonstrates statistically significant and consistent efficacy in AA with a favorable safety profile,” the researchers wrote.

Mild Adverse Effects, but No Placebo Arm and a Reality Check From Larger Trials

Adverse effects occurred in about one-third of patients across the pooled studies, were generally mild, and did not lead any patient to stop treatment. Because the included studies were overwhelmingly open-label case series and small cohorts rather than placebo-controlled trials, however, there was no comparison group against which to judge how much of that adverse event rate, or the regrowth seen, was attributable to the drug itself.

The 89% SALT 20 or less response rate in this pooled analysis of small studies stands in sharp contrast to 2 subsequent phase 3, placebo-controlled trials of upadacitinib in severe alopecia areata, which found SALT 20 or less response rates of 44.6% to 45.2% with the 15-mg dose and 54.3% to 55.0% with the 30-mg dose at week 24, vs 1.5% to 3.4% with placebo.²

That gap illustrates a familiar limitation of pooling small, open-label, and likely publication-biased studies: without a placebo arm or the scrutiny of trial-level reporting standards, such analyses tend to overstate how a drug will perform in a broader, less selected patient population, as the larger randomized trials later suggested for upadacitinib in alopecia areata.

For clinicians weighing off-label upadacitinib against the 2 drugs already approved for alopecia areata, this meta-analysis offers an early, favorable but likely inflated signal, while the placebo-controlled trial data provide a more reliable basis for setting expectations with patients. For payers, the disparity between early observational estimates and rigorous trial results is a reminder to weight coverage decisions toward the latter.

References

1. Barnawi G, Lazarowitz R, Nukaly HY, et al. Efficacy of upadacitinib for the treatment of alopecia areata: a systematic review and meta-analysis. J Am Acad Dermatol. 2026;95(4):1155-1158. doi:10.1016/j.jaad.2026.06.013
2. Mostaghimi A, Gooderham MJ, Lynde C, et al. Upadacitinib for severe alopecia areata in adults and adolescents: two phase 3 UP-AA randomized clinical trials. JAMA Dermatol. Published online August 12, 2026. doi:10.1001/jamadermatol.2026.2853